Objective: To test the effects of Tanshinone IIA (Tan IIA) on cell viability, cycle, apoptosis, and autophagy of human glioma cell U251 by regulating phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signal pathway. Methods: Tan IIA and PI3K agonist (740 Y-P) were used to treat glioma cells U251. MTT assay was used to assess cell viability and flow cytometry was used to detect cell apoptosis and cell cycle. The expressions of apoptosis-related proteins (Bcl-2 and Bax), autophagy-related proteins (LC3B and Beclin 1) and PI3K/Akt/mTOR signal pathway-associated proteins (p-PI3K, p-Akt and p-mTOR) were evaluated by Western blotting. Results: Tan IIA decreased the expression of p-PI3K and p-Akt proteins, inhibited cell viability and promoted apoptosis. Meanwhile, the expression of Bax increased, while the expression of Bcl-2 decreased. In addition, Tan IIA promoted autophagy in U251 glioma cells and raised the expression of LC3B and Beclin 1. However, 740 Y-P played a reversed role of Tan IIA in cell viability, cycle, apoptosis, and autophagy of U251 cells. Conclusion: Tan IIA could suppress the viability of U251 cells and induce cell apoptosis and autophagy, which might be related to the inhibition of the PI3K/Akt/mTOR signal pathway.

1.
Wang Y, Li J, Zhang Y, Yin H, Han B: CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett 2015;367:122-128.
2.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
3.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
4.
Liu Y, Yan W, Zhang W, Chen L, You G, Bao Z, Wang Y, Wang H, Kang C, Jiang T: MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. Oncol Rep 2012;28:1013-1021.
5.
Zhang L, Tong X, Li J, Huang Y, Hu X, Chen Y, Huang J, Wang J, Liu B: Apoptotic and autophagic pathways with relevant small-molecule compounds, in cancer stem cells. Cell Prolif 2015;48:385-397.
6.
Karsli-Uzunbas G, Guo JY, Price S, Teng X, Laddha SV, Khor S, Kalaany NY, Jacks T, Chan CS, Rabinowitz JD, White E: Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov 2014;4:914-927.
7.
Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004;11: 448-457.
8.
Shinojima N, Yokoyama T, Kondo Y, Kondo S: Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy 2007;3:635-637.
9.
Liu GY, Bu X, Yan H, Jia WW: 20S-protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and -independent pathways. J Nat Prod 2007;70:259-264.
10.
Zhang C, Jia X, Wang K, Bao J, Li P, Chen M, Wan JB, Su H, Mei Z, He C: Polyphyllin VII induces an autophagic cell death by activation of the JNK pathway and inhibition of PI3K/AKT/mTOR pathway in HepG2 cells. PLoS One 2016;11:e0147405.
11.
Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-5728.
12.
Cao Y, Klionsky DJ: Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein. Cell Res 2007;17:839-849.
13.
Metgud R, Gupta K: Expression of cell cycle and apoptosis-related proteins in ameloblastoma and keratocystic odontogenic tumor. Ann Diagn Pathol 2013;17:518-521.
14.
Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Hildt E, Hutzler P, Kochs E: The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 2003;96:524-531, table of contents.
15.
Delbridge AR, Grabow S, Bouillet P, Adams JM, Strasser A: Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis. Oncogene 2015;34:1872-1876.
16.
Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, Loeffler JS: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004;22:1926-1933.
17.
Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA: Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010;3:ra81.
18.
Eng CH, Abraham RT: The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming. Oncogene 2011; 30:4687-4696.
19.
Zhang Y, Wei RX, Zhu XB, Cai L, Jin W, Hu H: Tanshinone IIA induces apoptosis and inhibits the proliferation, migration, and invasion of the osteosarcoma MG-63 cell line in vitro. Anticancer Drugs 2012;23:212-219.
20.
Won SH, Lee HJ, Jeong SJ, Lu J, Kim SH: Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells. Phytother Res 2012;26:669-674.
21.
Zhu YQ, Wang BY, Wu F, An YK, Zhou XQ: Influence of tanshinone IIA on the apoptosis of human esophageal EC-109 cells. Nat Prod Commun 2016;11:17-19.
22.
Chen G, Liang Y, Liang X, Li Q, Liu D: Tanshinone IIA inhibits proliferation and induces apoptosis through the downregulation of survivin in keloid fibroblasts. Ann Plast Surg 2016;76:180-186.
23.
McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM: Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010;10 (suppl 3):S59-S65.
24.
Su CC, Chiu TL: Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. Oncol Rep 2016.
25.
Qian X, Dong H, Hu X, Tian H, Guo L, Shen Q, Gao X, Yao W: Analysis of the interferences in quantitation of a site-specifically PEGylated exendin-4 analog by the Bradford method. Anal Biochem 2014;465:50-52.
26.
Chen J, Shi DY, Liu SL, Zhong L: Tanshinone IIA induces growth inhibition and apoptosis in gastric cancer in vitro and in vivo. Oncol Rep 2012;27:523-528.
27.
Wang JF, Feng JG, Han J, Zhang BB, Mao WM: The molecular mechanisms of Tanshinone IIA on the apoptosis and arrest of human esophageal carcinoma cells. Biomed Res Int 2014;2014:582730.
28.
Xie J, Liu J, Liu H, Liang S, Lin M, Gu Y, Liu T, Wang D, Ge H, Mo SL: The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line. Acta Pharm Sin B 2015;5:554-563.
29.
Wang J, Wang X, Jiang S, Yuan S, Lin P, Zhang J, Lu Y, Wang Q, Xiong Z, Wu Y, Ren J, Yang H: Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J Neurooncol 2007;82:11-21.
30.
Tang C, Xue HL, Huang HB, Wang XG: Tanshinone IIA inhibits constitutive STAT3 activation, suppresses proliferation, and induces apoptosis in rat C6 glioma cells. Neurosci Lett 2010;470:126-129.
31.
Yang L, Guo H, Dong L, Wang L, Liu C, Wang X: Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells. Oncol Rep 2014;32:1303-1311.
32.
Liu P, Cheng H, Roberts TM, Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-644.
33.
Santarpia L, Lippman SM, El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:103-119.
34.
Bai H, Li H, Li W, Gui T, Yang J, Cao D, Shen K: The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget 2015;6:25520-25532.
35.
Deng L, Chen J, Zhong XR, Luo T, Wang YP, Huang HF, Yin LJ, Qiu Y, Bu H, Lv Q, Zheng H: Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in chinese women. PLoS One 2015;10:e0120511.
36.
Yuge K, Kikuchi E, Hagiwara M, Yasumizu Y, Tanaka N, Kosaka T, Miyajima A, Oya M: Nicotine induces tumor growth and chemoresistance through activation of the PI3K/AKT/mTOR pathway in bladder cancer. Mol Cancer Ther 2015;14:2112-2120.
37.
Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L: PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 2016;7:33440-33450.
38.
Su CC, Chiu TL: Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma ags cells both in vitro and in vivo. Oncol Rep 2016;36:1173-1179.
39.
Su CC: Tanshinone IIA inhibits human gastric carcinoma AGS cell growth by decreasing BiP, TCTP, Mcl1 and BclxL and increasing Bax and CHOP protein expression. Int J Mol Med 2014;34:1661-1668.
40.
Hu T, Wang L, Zhang L, Lu L, Shen J, Chan RL, Li M, Wu WK, To KK, Cho CH: Sensitivity of apoptosis-resistant colon cancer cells to tanshinones is mediated by autophagic cell death and p53-independent cytotoxicity. Phytomedicine 2015;22:536-544.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.